ATAI Life Sciences AG Amends COMPASS Pathways Stake Filing
Ticker: CMPS · Form: SC 13D/A · Filed: Sep 27, 2024 · CIK: 1816590
| Field | Detail |
|---|---|
| Company | Compass Pathways PLC (CMPS) |
| Form Type | SC 13D/A |
| Filed Date | Sep 27, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $6.05 |
| Sentiment | neutral |
Sentiment: neutral
Topics: ownership-change, sec-filing, schedule-13d
Related Tickers: CMPS
TL;DR
ATAI Life Sciences AG updated its 13D filing for COMPASS Pathways plc. Watch for ownership changes.
AI Summary
ATAI Life Sciences AG, through its filing on September 27, 2024, has amended its Schedule 13D regarding its holdings in COMPASS Pathways plc. The filing indicates a change in the beneficial ownership of COMPASS Pathways plc ordinary shares by ATAI Life Sciences AG.
Why It Matters
This amendment to a Schedule 13D filing signals a potential shift in significant ownership or strategy by a major shareholder in COMPASS Pathways plc, which could impact the company's stock price and future direction.
Risk Assessment
Risk Level: medium — Schedule 13D filings often indicate significant ownership changes or intentions by large investors, which can lead to market volatility.
Key Players & Entities
- ATAI Life Sciences AG (company) — Filing entity
- COMPASS Pathways plc (company) — Subject company
- Ryan Barrett (person) — Contact person for ATAI Life Sciences AG
FAQ
What is the primary purpose of this SC 13D/A filing?
The filing is an amendment to a Schedule 13D, indicating a change in the beneficial ownership or other relevant information regarding the securities of COMPASS Pathways plc by ATAI Life Sciences AG.
Who is the filing entity and what company is the subject of the filing?
The filing entity is ATAI Life Sciences AG, and the subject company is COMPASS Pathways plc.
When was this amendment filed?
This amendment was filed on September 27, 2024.
What is the CUSIP number for COMPASS Pathways plc ordinary shares?
The CUSIP number for COMPASS Pathways plc ordinary shares is 20451W101.
Who is listed as a contact person for ATAI Life Sciences AG in this filing?
Ryan Barrett is listed as a contact person for ATAI Life Sciences AG.
Filing Stats: 875 words · 4 min read · ~3 pages · Grade level 13.2 · Accepted 2024-09-27 19:56:26
Key Financial Figures
- $6.05 — 2,660,000 Ordinary Shares at a price of $6.05 per share in an open market transaction
Filing Documents
- ef20036450_sc13da.htm (SC 13D/A) — 66KB
- 0001140361-24-042244.txt ( ) — 67KB
(a) – (b) of the Schedule 13D is amended and restated in its entirety by inserting the following information
Item 5(a) – (b) of the Schedule 13D is amended and restated in its entirety by inserting the following information: As of the date of this Schedule 13D, ATAI AG beneficially owns 6,905,774 Ordinary Shares, representing approximately 10.1% of the 68,388,194 Ordinary Shares outstanding as of July 29, 2024. ATAI AG is a wholly owned subsidiary of ATAI N.V., and as a result, ATAI N.V. may be deemed to share beneficial ownership of the Ordinary Shares held by ATAI AG.
(c) of the Schedule 13D is hereby amended and supplemented as follows
Item 5(c) of the Schedule 13D is hereby amended and supplemented as follows: On September 26, 2024 ATAI AG sold 2,660,000 Ordinary Shares at a price of $6.05 per share in an open market transaction on the Nasdaq Global Select Market. Except for the foregoing transaction, during the past 60 days neither the Reporting Persons nor any Related Person has effected any transactions in the Ordinary Shares.
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date : September 27, 2024 ATAI LIFE SCIENCES AG By: /s/Anne Johnson Name: Anne Johnson Title: Chief Financial Officer ATAI LIFE SCIENCES N.V. By: /s/ Anne Johnson Name: Anne Johnson Title: Chief Financial Officer